[Medical and ventilatory treatment of XXXX ].

@entity1 @entity712 @entity452 @entity25394 @entity3362 @entity26 @entity1507 @entity551 @entity891 @entity1286 @entity6759 @entity7604 @entity204
BACKGROUND: Traditional medical treatment of @entity712 has remained unchanged for many years. It has been based on @entity26 supplementation and mechanical ventilatory support as well as the administration of @entity1286 , diuretics, @entity3362 and inotropic agents. In 2005 the European Society of Cardiology published new guidelines on diagnosis and treatment. Also, new therapies have been introduced recently, giving rise to changes in therapeutic concepts. MATERIAL AND METHOD: The article is based on these new guidelines and recent studies selected from the literature. RESULTS: Mechanical ventilatory support reduces the number of @entity1 who require endotracheal intubation. @entity3362 in higher dosages than employed today appear to be beneficial to @entity1 with @entity891 , probably because of the pronounced afterload reducing effect. Nesiritide has shown better haemodynamic effects than common @entity1507 dosages in @entity1 with @entity712 . @entity25394 was tested in the biggest trial ever which, however, was terminated prematurely, because of futility with regard to the endpoints dyspnoea and @entity204 . @entity452 and @entity7604 are associated with increased mortality in @entity1 with pronounced chronic and acute @entity712 . Levosimendan has shown lower mortality compared to @entity452 in @entity1 with acute @entity712 . INTERPRETATION: New concepts have finally emerged, including the application of old drugs such as @entity3362 in new (i.e., higher) dosages, as well as the novel compound @entity6759 , and hypoperfused organs without severe @entity551 . The new European Society of Cardiology classification provides a valuable and long-awaited guideline to diagnosis and treatment.
